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Alejandra Rangel1, Brent Race1, Mikael Klingeborn2, James Striebel1 and Bruce Chesebro1,3*Abstract
Background: In some prion diseases, misfolded aggregated protease-resistant prion protein (PrPres) is found in
brain as amyloid, which can cause cerebral amyloid angiopathy. Small diffusible precursors of PrPres amyloid might
flow with brain interstitial fluid (ISF), possibly accounting for the perivascular and intravascular distribution of PrPres
amyloid. We previously reported that PrPres amyloid in scrapie-infected transgenic mice appeared to delay
clearance of microinjected brain ISF tracer molecules.
Results: Here we studied distribution of PrPres amyloid on capillaries, arteries and veins to test whether vascular
specificity of PrPres corresponded to distribution of ISF tracer molecules. To distinguish PrPres-positive arteries from
veins and capillaries, scrapie-infected mouse brains were studied by immunodetection of alpha smooth muscle
actin. ISF was studied using fluorescein-labeled ovalbumin microinjected into brain as a tracer. In infected
preclinical or clinical mice, PrPres was found mostly on capillaries (73-78%). Lower levels were found on arteries
(11-14%) and veins (11-13%). Compared to PrPres, ISF tracer was found at higher levels on capillaries (96-97%), and
the remaining tracer was found at a skewed ratio of 4 to 1 on arteries and veins respectively.
Conclusions: PrPres association with blood vessels suggested that ISF flow might transport diffusible PrPres
precursor molecules to perivascular sites. However, the different vascular specificity of PrPres and ISF tracer
indicated that ISF flow did not alone control PrPres dissemination. Possibly blood vessel basement membrane (BM)
components, such as glucosaminoglycans, might concentrate small PrPres aggregates and serve as scaffolds for PrP
conversion on multiple vessel types.
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Basement membraneBackground
TSE diseases or prion diseases are a rare group of slow
neurodegenerative brain diseases which affect humans as
well as a variety of domestic and wild mammals. In
prion diseases normal host-encoded cell surface-
anchored prion protein (also known as PrPC or PrPsen
due to its sensitivity to protease digestion) undergoes
misfolding and aggregation to generate a partially* Correspondence: bchesebro@nih.gov
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reproduction in any medium, provided the orprotease-resistant form known as PrPres or PrPSc, which
is detectable by immunoblot and is an important bio-
chemical marker for the disease (for reviews see [1,2]).
PrPres may also be a causal factor in the associated brain
damage observed. Neuropathology of prion diseases in
humans and in animals, such as sheep, cattle and ro-
dents, is typically characterized by gray matter vacuol-
ation and gliosis, as well as deposition of PrPres in
either a diffuse non-amyloid form or a more dense amyl-
oid form. Diffuse PrPres is the more common form and
is seen in human sporadic CJD as well as in most types
of animal prion diseases [3-6]. The amyloid form of
PrPres is seen in many familial human prion diseases as-
sociated with PrP mutations as well as in certain animal
prion disease models [7-9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anchored to the cell surface by a glycophosphatidylinositol
(GPI) linkage. Previously we generated transgenic Tg44
mice, which express only the anchorless form of PrP, and
in these mice scrapie-infection results in an unusual type
of slow fatal prion brain disease distinguished by wide-
spread deposition of PrPres amyloid in the central nervous
system [10] and in extraneural sites such as heart, brown
fat, white fat and colon [11,12]. In the CNS of infected
Tg44 mice the gray matter vacuolation typical of prion
diseases is minimal, and PrPres is primarily deposited as
perivascular and intravascular amyloid which is associated
with extensive non-vacuolar neuronal damage as well as
astrogliosis and microgliosis [10].
The perivascular PrPres amyloid deposition and asso-
ciated pathology seen in scrapie-infected Tg44 mice is
similar to cerebral amyloid angiopathy (CAA) seen in
several familial brain amyloid diseases involving mutant
proteins or peptides (for review see [13]). In the case of
prion diseases, PrP mutations including Y145X, Q160X,
Y163X and Y226X [13-16] have been associated with de-
velopment of CAA with perivascular PrPres amyloid,
and all these mutations give rise to truncated PrP mole-
cules which also lack the glycophosphatidylinositol (GPI)
anchor. Interestingly, one other human patient express-
ing PrP Q227X which lacks the GPI anchor had disease
with multicentric plaques and no CAA [15]. In humans
CAA is most commonly observed with Alzheimer’s dis-
ease (AD) where Aβ amyloid is deposited in CNS as
both vascular and parenchymal plaques. In CAA associ-
ated with Alzheimer’s disease, small arteries and arterioles
are the most common sites of Aβ amyloid deposition
[13,17,18], but amyloid is also detected in capillaries and
in veins at a lower incidence [18-20]. In leptomeningeal
vessels of AD patients the ratio of Aβ-positive arteries to
veins was 4.5 to 1 [21]. This Aβ amyloid distribution mir-
rored the pattern of the bulk flow of brain interstitial fluid
(ISF) tracers which appear to drain from the brain in peri-
vascular spaces of arteries more than veins [22,23],
suggesting that ISF flow might play a role in the vascular
distribution of amyloid in AD [24].
In our work with Tg44+/+ mice, we previously ob-
served PrPres amyloid plaques associated with various
brain blood vessels which appeared to include arteries,
capillaries and veins based on morphological criteria [10].
In the present work using dual staining with anti-PrP
monoclonal antibody plus antibody reactive with alpha
smooth muscle actin (ASMA) in arteries and arterioles,
we studied the vascular specificity of PrPres amyloid
distribution in scrapie-infected Tg44+/+ mice. The dis-
tribution pattern of PrPres amyloid on blood vessels in
this model appeared to be different than that of Aβ
amyloid observed in humans with AD, and suggested




Homozygous Tg44+/+ mice expressing a transgene en-
coding mouse prion protein lacking the GPI anchor (an-
chorless PrP) were described previously [25]. Mice from
4–6 weeks of age were infected with 1% brain homogen-
ate of RML scrapie stock using intracerebral (IC) or
intravenous (IV) routes using volumes of 50 μl and
250 μl respectively as previously described [26-28]. Un-
infected age-matched Tg44+/+ mice and non-transgenic
C57BL/10SnJ mice were also used in some experiments.
All mice were housed at Rocky Mountain Laboratories
(RML) in an AAALAC-accredited facility and experimen-
tation followed NIH RML Animal Care and Use Commit-
tee (ACUC) approved protocols (protocol # 2010–08).
Stereotaxic surgery
Intracerebral injections of FITC-OVA were performed
on uninfected and scrapie-infected Tg44+/+ mice and
uninfected C57BL/10 adult male mice as previously de-
scribed [27]. Mice weighing approximately 30 g were used
to improve accuracy of stereotaxic injection. Scrapie-
infected Tg44+/+ mice were injected at 250–280 dpi
which was the time of early clinical disease. Uninfected
C57BL/10 and Tg44+/+ mice were age-matched to
scrapie-infected mice. All injections used 0.5 μl FITC-
OVA solution at a rate of 0.25 μl/min. Mice were eutha-
nized 30 min or 7 hours post-injection.
Primary antibodies
The following primary antibodies were used: rabbit poly-
clonal antibody anti-alpha-smooth muscle actin (ASMA)
(1:500) (Abcam, ab5694). Human D13 anti-PrP recombin-
ant antibody was obtained from tissue culture superna-
tants made in our laboratory from CHO cells expressing
the D13 antibody construct [29], which were kindly pro-
vided by Dr. R. Anthony Williamson, The Scripps Re-
search Institute, La Jolla, CA [27]. D13 culture fluid was
used at a dilution of 1:100. Primary antibodies were di-
luted in PBS with 1% normal goat serum and 0.1% Triton
X-100. Diluent without antibody was used as a negative
control.
Immunohistochemical staining
Mice were deeply anesthetized with isoflurane and
cervically dislocated. Brains were removed, fixed in
neutral-buffered formalin (NBF), embedded in paraffin,
and processed for immunohistochemical staining for
PrPres using D13 monoclonal antibody and detection
with DAB chromogen as previously described [26]. Fol-
lowing the DAB step, slides were stained with rabbit
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(AbCam, Cambridge, MA) (dilution 1:450) and develop-
ment with avidin-alkaline phosphatase using Fast Red
chromogen (Ventana, Tucson, AZ). Hematoxylin was
used as a counter stain for nuclei.
Immunofluorescence staining
Mice were deeply anaesthetized with isoflurane, intracar-
dially perfused with PBS followed by 4% paraformalde-
hyde in phosphate buffer, pH 7.4, and brains were
removed, immersion fixed in 4% paraformaldehyde over-
night, cryoprotected, and frozen sections were prepared
and stained using the Dako Autostainer Plus (Dako,
Carpentaria, CA) as previously described [27]. ASMA
staining alone or co-staining with D13 anti-PrP mono-
clonal antibody followed by anti-ASMA were performed
depending on the analysis. Prior to immunofluorescence
staining for PrPres, frozen sections on slides were incu-
bated for 15 min at room temperature in 4.0 M guan-
idine thiocyanate to expose antigenic epitopes of PrPres.
Slides were rinsed with diluent and then exposed to
D13 for 1 hour at room temperature. After washing with
diluent, slides were exposed to Alexa-Fluor 488-tagged
secondary goat anti-human Ig antibodies (Molecular
Probes, Eugene, OR) for 30 min at a 1:200 dilution. After
rinsing with diluent, slides were exposed to rabbit anti-
ASMA for 1 hour at room temperature, followed by rins-
ing with diluent and exposure to Alexa-Fluor 568-tagged
secondary goat anti-rabbit Ig for 30 min at a dilution of
1:200. In some cases slides from mice previously injected
with FITC-OVA were stained only with anti-ASMA using
the protocol above without the guanidine and D13 steps.
Nuclei were stained with 0.01% 4′,6-diamidino-2-
phenylindole dilactate (DAPI, Invitrogen) for 5 min and
rinsed with double-distilled H2O, and coverslips were
applied to tissue sections with ProLong Gold Antifade
reagent (Invitrogen). Slides were examined and photo-
graphed either in an epifluorescent Olympus BX51 micro-
scope (Olympus, Center Valley, PA) with Microsuite FIVE
software (Olympus) or in a confocal laser-scanning micro-
scope (Zeiss, SLM 510, Carl Zeiss, Germany). For all con-
focal imaging a Z-stack of 7 to 30 optical sections of
0.38 μm thickness was taken. All images were obtained in
sequential scanning laser mode to avoid fluorochrome
cross-excitation. Images were managed using Imaris soft-
ware (Bitplane, So.Windsor, CT).
Identification and quantitation of blood vessels
Multiple photomicrographs of representative fields were
examined to quantitate vessel types as described below.
Numbers of mice and total areas examined are given in
the table footnotes. Sections were obtained at 110 μm
intervals, and photomicrographs including areas of the
cerebral cortex, hippocampus, thalamus, hypothalamusand striatum were counted. Blood vessels associated
with PrPres or FITC-OVA were identified on the basis
of ASMA staining and blood vessel lumen size. The ma-
jority of vessels detected were obvious capillaries which
were ASMA-negative and had a lumen size ranging from
3-7 μm. ASMA-negative vessels with lumen size 8 μm
or larger were considered to be veins or venules.
ASMA-positive vessels with thicker walls were consid-
ered to be arteries or arterioles. Occasional ASMA-
positive vessels had large lumens and thin walls and
were scored as veins. An example is shown in Figure 1d.
Results
Cerebral vascular distribution of PrPres in scrapie-infected
Tg44+/+ mice
To identify the blood vessel types associated with PrPres
amyloid plaques in brain, scrapie-infected Tg44+/+ mice
were studied during early clinical disease from 250–280
dpi. For immunological studies, brain sections were
processed for dual immunofluorescence (IF) using hu-
manized monoclonal antibody D13 for detection of
PrPres and rabbit anti-ASMA. Numerous PrPres plaques
of varying size were seen in most brain regions. Plaques
in Tg44 mice appeared to begin at the blood vessel base-
ment membrane, as seen previously by EM studies [10],
and extended into the adjacent parenchyma up to 10–
100 microns away from the original blood vessel wall
(Figure 1a, b and g).
Arteries, veins and capillaries were identified and dis-
tinguished as described in the Methods. We counted
photographic fields of brains from 4 mice. Of 152
PrPres-positive vessels initially counted 73% were capil-
laries, 14% were arteries, and 13% veins (Table 1). The
equal incidence of PrPres positive arteries and veins was
unexpected as this was not seen with Aβ amyloid in
humans with AD or mouse AD models [21,30]. To in-
crease our confidence in these data we studied addi-
tional fields in 6 mice counting only the vessels larger
than capillaries. Here, out of 140 PrPres-positive large
vessels, 43% were ASMA-positive arteries or arterioles
and 57% were ASMA-negative veins (Table 2). Thus,
PrPres appeared to be associated equally with arteries
and veins, but showed a preferential association with
capillaries.
The above IF method was very sensitive for detecting
ASMA. However, identification of ASMA-negative capil-
laries and veins was hampered by the lack of a specific
positive marker for these types of vessels. Therefore, we
also studied scrapie-infected clinical Tg44 mice at
308 dpi using immunohistochemical staining of paraffin
sections for PrPres and ASMA where staining with
hematoxylin facilitated visualization of nuclei and other
tissue structures including vessels walls and allowed eas-
ier distinguishing of veins and capillaries. Using IHC
Figure 1 Immunofluorescence detection of PrPres and ASMA in brain tissue of scrapie-infected Tg44+/+ mice. Mice were examined at
250–280 dpi which correlates with early clinical signs [10,27]. PrPres was detected with D13 monoclonal antibody (green) and ASMA was
detected with rabbit anti-ASMA (red) as described in the Methods section. (a) Overview photo showing PrPres plaques (green) and ASMA
detection (red). Several capillaries (yellow arrows), one venule (arrowhead) and one arteriole (pink arrow) are shown associated with PrPres
plaques. (b) Three separate PrPres plaques (green) are seen. One has a central ASMA-positive arteriole (arrow) and the other two have a central
vein (arrowheads). (c) Several capillaries (arrows) and one venule (arrowhead) are located in a group of small PrPres plaques. (d) PrPres plaques in
meninges and adjacent parenchyma associated with 4 ASMA-positive arteries or arterioles (arrow) and two veins (arrowheads). (e) PrPres plaque
with ASMA-negative vein (arrowhead). (f and g) PrPres plaques with associated ASMA-positive arterioles (arrows). Bars: 25 μm (b and f), 50 μm
(a, c, d, e, and g).
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typical field with many PrPres-positive capillaries, sev-
eral PrPres-positive veins and venules and two PrPres-
positive arterioles. Again many plaques extended quite
far into the parenchyma surrounding even small vessels
(Figure 2a). At higher magnification ASMA-negative ca-
pillaries and veins could be distinguished by size dif-
ferences, and vessel walls were thin in both cases(Figure 2b). In Figure 2c an ASMA-negative capillary
was clearly different from a thicker-walled ASMA-
positive small artery. In Figure 2d a larger thick-walled
ASMA-positive meningeal artery with a visible elastica
layer was located adjacent to PrPres-positive brain par-
enchyma. In Figure 2e a vein, capillary and arteriole were
easily distinguished by ASMA-staining as well as wall
thickness and lumen size.
Table 1 Immunofluorescence detection of PrPres on







Artery to Vein (A/V) ratio 1.05 to 1
a - Vessels were defined as described in the Methods section.
b - N = number of PrP-res-positive vessels of each type detected in the total
area counted. Total area counted was 7.5 mm2 . Data are from 4 individual
mice, which were analyzed between 250–280 days post-infection with RML
scrapie as described in the Methods.
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259 PrPres-positive vessels were counted from three dif-
ferent mice. 78.4% were capillaries, 10.8% were arteries
and 10.8% were veins (Table 3). The high incidence of
PrPres associated with capillaries and the lower inci-
dence of PrPres on both arteries and veins was very
similar to the results seen above using immunofluores-
cence. The finding of PrPres on all three blood vessel
types suggested the possibility that PrPres might spread
through the brain by transport via the brain ISF bulk
flow as ISF tracers are known to accumulate along the
walls of all these vessel types [22,30]. This process might
also be enhanced by affinity of PrPres for certain compo-
nents of blood vessel walls. An alternative explanation
for the association of PrPres with blood vessels might be
redistribution of PrPres in the brain via hematogenous
spread of PrPres seeds.
Evidence against hematogenous spread of scrapie
infection to brain in Tg44+/+ mice
To study whether hematogenous spread of scrapie
PrPres to the CNS occurred in Tg44+/+ mice we com-
pared inoculation of scrapie by intracerebral (i.c.) and
intravenous (i.v.) routes. In our previous studies, i.c.
scrapie inoculation of Tg44+/+ mice led to appearance
of PrPres amyloid in brain and extraneural tissues, in-
cluding spleen, heart, brown fat, white fat, tongue,Table 2 Immunofluorescence detection of PrPres on





A/V ratio 0.75 to 1
a - Vessels were defined as described in the Methods section.
b - N = number of PrP-res-positive vessels of each type detected. The total area
counted was 22.53 mm2. Data are from 6 mice which were analyzed between
250–280 days post-infection with RML scrapie as described in the Methods.skeletal muscle and colon, starting at 150 dpi [11,12],
and clinical disease requiring euthanasia occurred from
310-340 dpi [10]. In contrast, i.v. scrapie inoculation of
Tg44+/+ mice did not induce any detectable brain
PrPres from 150-350 dpi, even though extensive infec-
tion of extraneural tissues occurred (Table 4). At later
times, from 450-600 dpi, a few mice inoculated by the i.v.
route had detectable PrPres amyloid in brain [26]. The
route of actual CNS invasion in these mice might have
been either via slow neural transport [26] or via blood, if
the blood–brain-barrier (BBB) were less efficient at later
ages; however, this could not be determined by our experi-
ments. The discrepancy between brain and extraneural in-
fection after i.v. inoculation suggested that the BBB could
prevent neuroinvasion of the brain by PrPres from the
blood. The protective role of the BBB against hema-
togenous seeding of brain by PrPres was supported by ex-
periments where a 100% incidence of brain infection was
noted after a needle stab wound was made in brain imme-
diately after i.v. scrapie inoculation (Table 4).
In summary, hematogenous infection of brain after i.v.
scrapie inoculation was a late and infrequent occurrence
in Tg44+/+ mice. Thus, hematogenous redistribution of
PrPres seeds would not explain the widespread perivas-
cular distribution of PrPres amyloid found in the brains
of these mice. In contrast, dispersion of PrPres by ISF
flow remained a likely possibility to explain the observed
pattern of perivascular PrPres amyloid.
Analysis of the vascular distribution of a brain ISF tracer
in Tg44+/+ mice
We previously studied the interaction between scrapie-
induced PrPres and the ISF drainage system in Tg44+/+
mice [27]. In these experiments amyloid PrPres transi-
ently blocked the ISF drainage system as measured by
tracers of several different sizes. In contrast, no blockage
of ISF drainage was seen in the presence of non-amyloid
PrPres in non-transgenic mice. However, in these studies
we did not determine the relative distribution of ISF
tracer on the different vessels. Therefore, in the present
study we determined the vascular distribution of an ISF
tracer in Tg44+/+ mice to measure the association of
ISF tracer with capillaries, arteries and veins.
Using fluorescein isothiocyanate (FITC)-labeled ov-
albumin (OVA) as the ISF tracer, mice were injected
with 0.5 μl tracer in the striatum. At 30 minutes and
7 hours post-injection, mice were euthanized and brains
were fixed. Cryosections near the injection site were
double-stained with antibodies specific for ASMA to
identify arteries and arterioles, and sections were exam-
ined by immunofluorescence microscopy (Figure 3).
At 30 minutes post-injection of tracer in uninfected
Tg44+/+ mice, 96-97% of the tracer-positive vessels were
capillaries and the remaining 3-4% were veins and
Figure 2 Immunohistochemical detection of ASMA and PrPres in scrapie-infected Tg44+/+ transgenic mice at 308 dpi. (a) Overview
showing perivascular PrPres amyloid plaques (brown) and ASMA (pink) in cerebral cortex. Note association of PrPres plaques with capillaries
(green arrowheads), veins (black arrows) and arteries (green arrows). (b) Higher magnification of perivascular PrPres on a large ASMA-negative
vein (black arrow) and a small capillary (green arrowhead). (c) PrPres surrounding an artery (green arrow) and a capillary (green arrowhead).
(d) ASMA-positive leptomeningeal artery with thin ablumenal ring of PrPres (green arrow). (e) Leptomeningeal vein (black arrow) with adjacent
PrPres. In lower area a small artery (green arrow) and a capillary (green arrowhead) have associated PrPres. Bars: 100 μm (a), 50 μm (b-e).
Table 4 Comparison of induction of PrPres amyloid at
150–350 days post-infection in brain versus extraneural
tissues after different inoculation routes
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laries was similar to our previous data where both 5 and
30 minute time-points were studied in uninfected and
scrapie-infected non-transgenic C57BL/10 mice and in
Tg44+/+ mice [27]. To determine the ratio of tracer as-
sociation with arteries to veins more large vessels were
counted by examining additional microscopic fields in
both uninfected and infected Tg44+/+ mice. In these re-
sults ovalbumin-positive large vessels in uninfected miceTable 3 Immunohistochemical detection of PrPres on







A/V ratio 1 to 1
a - Vessels were defined as described in the Methods section.
b - N = number of PrP-res-positive vessels of each type detected. The total area
counted was 12 mm2. Data are from 3 individual mice, which were analyzed at
308 days post-infection with RML scrapie as described in the Methods.were 82% arteries and 18% veins (A:V ratio = 4.6 to 1),
and scrapie-infected mice were similar with 79% arteries
and 21% veins (A:V ratio = 3.8 to 1) (Table 6). At 7 h
after tracer injection in uninfected mice, tracer was




i.v. with stab 8/8 8/8
a - Tg44+/+ mice were inoculated with RML scrapie by two routes (i.c,
intracerebral; i.v., intravenous) as described in the Methods. For some mice, i.v.
scrapie inoculation was followed immediately by a needle stab to the brain to
break the blood–brain-barrier. Some of these data were presented previously
in a different format [26].
b - Number of mice with PrPres amyloid in brain or extraneural organs (heart,
brown fat and colon) detected by immunohistochemistry/total mice inoculated.
c - From 450-600dpi 2 of 4 mice inoculated by the i.v. route had detectable PrPres
amyloid in brain. The route of actual CNS invasion in these mice might have been
either via slow neural transport or via blood, if the BBB was less efficient at later
ages. However, this could not be determined by our experiments.
Figure 3 Immunofluorescence detection of ASMA and FITC-OVA in uninfected Tg44+/+ mice at 30 min after stereotaxic microinjection
of tracer. ASMA is observed as red color and FITC-OVA tracer is green. (a) Epifluorescence, (b-e) Confocal optical sections of 0.38 μm thickness.
(a) Most tracer is associated with capillaries (arrows), but some tracer is associated with a larger venule (arrowhead). (b) ASMA-positive artery with
associated tracer. (c) Two ASMA-positive arteries with associated tracer. (d) ASMA-negative tracer-positive vein (arrowhead) with 25 μm diameter
and two smaller tracer-positive capillaries (arrows) for comparison. (e) ASMA-negative tracer-positive vein (17 μm diameter). Bars: 100 μm (a),
40 μm (b) and 20 μm (c-e).
Table 6 Immunofluorescence analysis of arteries and
veins in scrapie-infected and uninfected Tg44+/+ mice for
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nificantly different from the ratio seen at 30 min in unin-
fected Tg44+/+ mice by Fischer’s exact test (P = 0.36). In
summary, in Tg44+/+ mice the vascular distribution of
the ISF tracer and PrPres differed considerably. Although
both FITC-OVA and PrPres showed a high association
with capillaries, the percent was significantly higher for
FITC-OVA (96-97% versus 73-78%, p < 0.0001) (Table 5).
The artery to vein (A:V) ratios were also significantly dif-
ferent for FITC-OVA and PrPres, approximately 4 to 1 forTable 5 Immunofluorescence analysis of FITC-ovalbumin
association with capillaries, arteries and veins in
uninfected and scrapie-infected Tg44+/+ mice at 30 min
after microinjection of tracer
Uninfected Scrapie-infected
Vessels N % N %
Capillaries 1297 96 935 97
Arteries & Veins 50 4 29 3
Total 1347 100 964 100
Data are from 3 mice per group; mice were analyzed between 250–280 days
post-infection with RML scrapie as described in the Methods. Area counted:
Uninfected = 5.63 mm2. Scrapie-infected = 9.01 mm2. There was a highly
significant difference in numbers of capillaries versus arteries plus veins
associated with FITC-OVA (Table 5) versus PrPres (Table 1) in scrapie-infected
mice (P < 0.0001) by two-tailed Fischer’s exact test.FITC-OVA and 1 to 1 for PrPres (p < 0.0001)(Table 6).
Therefore, the ISF flow was not the only factor influencing
the distribution of PrPres in infected Tg44+/+ mice.
Discussion
Scrapie-infected Tg44+/+ mice expressing only the an-
chorless form of PrP were found previously to depositdetection of FITC-OVA at 30 min after microinjection of
tracer
Uninfected Scrapie-infected
Vessels N % N %
Arteries 78 82 152 79
Veins 17 18 40 21
Total 95 100 192 100
A/V ratio 4.6 to 1 3.8 to 1
Data are from 3 mice per group; mice were analyzed between 250–280 days
post-infection with RML scrapie as described in the Methods. Area counted:
Uninfected =10.88 mm2, scrapie-infected = 19.52 mm2. Results similar to those
in Tables 5 and 6 were also observed in uninfected C57BL/10 mice (data not
shown). Data for arteries and veins for uninfected versus scrapie-infected Tg44
+/+ mice were not significantly different by two-tailed Fischer’s exact test
(p = 0.64). In contrast, there was a highly significant difference in numbers of
arteries and veins associated with FITC-OVA (Table 6) versus PrPres (Table 2) in
scrapie-infected mice (P < 0.0001) by two-tailed Fischer’s exact test.
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vascular and intravascular distribution [10]. This disease
required scrapie infection, as it did not occur spontan-
eously in uninfected Tg44+/+ mice. The lack of the GPI
anchor group and the minimal amount of glycan on the
anchorless PrP are likely to contribute to the tendency
of anchorless PrP to form amyloid, but the reasons for
the vascular distribution are not known. In the current
studies of the vascular specificity of PrPres amyloid in
brain of Tg44 mice, amyloid accumulated mostly on ca-
pillaries (73-78%), but also was found on both small ar-
teries (11-14%) and veins (11-13%) (Tables 1 and 3). The
association of PrPres with all these blood vessel types
could be explained either by hematogenous re-
distribution of intracerebrally inoculated scrapie PrPres
or, alternatively by dissemination of PrPres via the flow
of ISF towards capillaries, small arteries and veins. Our
results on studies of mice after intravenous scrapie in-
oculation did not support the suggestion of hema-
togenous spread of scrapie infectivity and PrPres
(Table 4). Thus, the most likely explanation for the brain
perivascular PrPres distribution was dissemination of
small diffusible PrPres aggregates by the ISF flow.
Based on our present finding of PrPres amyloid on ca-
pillaries, arteries and veins, amyloid polymerization
might be initiated by some BM components, such as
glucosaminoglycans (GAGs), found on all of these types
of vessels [2,31]. GAGs were previously shown to bind
PrPsen [32] and block or potentiate PrP conversion
in vitro [33]. Therefore, GAGs in BM might serve asFigure 4 Cartoon depicting seeding of PrP conversion by fibrils of va
inoculation larger fibrils (green) might diffuse poorly in brain but would se
oligomeric fibrils (blue) may be too small to seed PrP conversion [34], but c
blood vessel basement membranes where they might be bound by glucos
oligomers might form a scaffold capable of seeding new PrPres generation
(orange) extending both radially and linearly around blood vessel. Smaller
new blood vessels and might initiate seeding at these distant sites.scaffold structures to concentrate, bind and/or align dif-
fusible PrPres aggregates which are too small to act
alone as seeds for further PrPres conversion. Presumably
after such re-alignment along a scaffold, these aggregates
might function effectively as seeds for PrP conversion
(Figure 4).
In contrast to the apparent involvement of blood ves-
sel components in PrPres amyloid formation, it was sur-
prising that amyloid plaques in this model often
extended large distances (10 to 100 μm) away from the
ablumenal blood vessel walls. Possibly, after establish-
ment at the BM, PrPres amyloid might act without
GAGs to self-scaffold further conversion of anchorless
PrP at locations quite distant from the blood vessel BM.
This conversion might also be increased by the abun-
dance of diffusible anchorless PrP which is secreted into
the extracellular space by many CNS cell types. In
addition, anchorless glycan-negative free-floating PrP in
extracellular spaces might have a greater tendency to
form amyloid compared to normal membrane-anchored
glycan-rich PrP [2].
Anchorless PrP, similar to that found in Tg44 mice,
has been detected in association with several different
human PrP mutations in patients with familial prion dis-
ease. In these cases, mutation of one PrP allele results in
aberrant C-terminal PrP truncation (Y145X, Q160X,
Y163X, Y226X, and Q227X) with production of short-
ened PrP lacking the GPI anchor moiety [13-16]. In
these patients PrP amyloid with CAA is often a predom-
inant neuropathological finding, and in the figuresrious sizes in injected scrapie brain homogenate. Following
ed PrP conversion (orange) locally near inoculation site. Smaller
an travel by diffusion and in brain interstitial fluid (ISF) flow towards
aminoglycans (GAGs) and other molecules. These concentrated
(orange) which in turn might self-scaffold further PrPres conversion
oligomers generated at this new site might travel in the ISF flow to
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specificity of the CAA appears to involve capillaries, ar-
teries and veins. This was similar to the Tg44 model, ex-
cept that in Tg44 mice capillary amyloid was more
prominent (Tables 1 and 3). With all the above-
mentioned human PrP mutations, the plaques appeared
to be located in blood vessel walls. In addition, in the
publications describing both the Y145X and Y226X mu-
tations, the plaques also extended up to 15-35 μm into
the parenchyma from the ablumenal vessel wall. This
was similar to infected Tg44 mice where the PrPres
amyloid plaques extended 10-100 μm into the surround-
ing brain tissue (Figure 1a-g and 2a-e). Thus, based on
vascular specificity, plaque size and plaque location,
neuropathology in humans with Y145X and Y226X was
similar to that seen in scrapie-infected Tg44 mice.
CAA has also been extensively observed in association
with Aβ amyloid deposits in Alzheimer’s disease pa-
tients, and CAA may be an important aspect of the
neuropathogenesis of AD [17,20,24,35-38]. Interestingly,
CAA in these patients differs from infected Tg44 mice
and from that seen in the Y145X and Y226X human PrP
truncation mutations described above. First, the amyloid
in Aβ CAA is mostly located within or very close to the
vessel walls [13,20], whereas PrPres amyloid appears to
extend quite far away from the vessel wall [10,14,15].
Second, in Aβ CAA the vascular specificity of the amyl-
oid deposition shows a preferential association with
small arteries compared to veins which is not seen in
PrPres CAA. For example, in the leptomeninges of AD
patients, in one study small arteries and arterioles
appeared to be the site of 80% of the amyloid, whereas
only 20% was associated with veins [21]. However, in a
different paper, the amyloid distribution in leptomenin-
geal vessels was arteries 56% and veins 45% [19]. There-
fore, there may be variation in this ratio among different
patients. In the cerebral cortex small arteries have been
described as the main site of amyloid deposition, with
lesser amounts of amyloid associated with veins, venules
or capillaries [20]. However, in a subset of AD patients
with CAA, designated Type 1-CAA, cortical Aβ amyloid
was associated with capillaries, arteries and veins [19],
and a role for capillary CAA in specific clinical dysfunc-
tion has been suggested [39,40]. Thus, based on the vas-
cular amyloid distribution, scrapie-infected Tg44 mice
appear to be somewhat similar to the group of CAA-type 1
Aβ patients.
The reasons for the vascular specificity of CAA involv-
ing various different amyloid proteins are not known.
Perhaps different proteins have differing requirements
for BM-derived co-factors for amyloid formation. If Aβ
amyloid were unable to self-scaffold efficiently in vivo so
that a blood vessel-derived co-factor was always re-
quired, Aβ amyloid deposition might be more restrictedto the blood vessel wall and less likely to extend out into
the parenchyma. Similarly, if vascular smooth muscle
cells, rather than BM, were the source of the essential
co-factor(s), this might restrict deposition of Aβ amyloid
to the walls of small arteries and arterioles which have
abundant smooth muscle cells, as opposed to veins
which have few smooth muscle cells. Perhaps capillary-
derived co-factors are involved in Aβ CAA type 1 where
capillary CAA is prominent [19].
The differences in PrPres and Aβ plaque size and vas-
cular distribution might also be influenced by numerous
other factors, including the rates of association, refolding
and dissociation of the amyloid complexes in different
sites, and the ability of glial cells and macrophages to
breakdown the amyloid. The large difference in size be-
tween Aβ (40–42 amino acids (aa)) versus anchorless
PrP (210aa in Tg44, 204aa in Y226X, and 120aa in
Y145X), might also act by influencing some of these
mechanisms. Single amino acid sequence differences
can also influence the vascular specificity of amyloid
deposition, as seen by differences between the effects
of Y226X and Q227X PrP mutations, where the
former is associated with CAA and the latter has par-
enchymal multicentric plaques without CAA [15].
However, the mechanisms of most of these effects re-
main unknown.
Many previous studies have followed clearance of ISF
tracers labeled with radioactive or fluorescent tags (for
review see [22,30,41,42]). In our previous work, tracer
was detectable on blood vessels at 30 min, much re-
duced at 7 hours and almost completely gone by
24 hours [27]. The present study provides quantitative
data on specificity of the ISF tracer FITC-OVA for capil-
laries, arteries and veins. At 30 min post-injection of
Tg44 mice we found the majority of tracer was associ-
ated with capillaries (96%), whereas arteries and veins
were much lower (3.2% and 0.8% respectively) (Tables 5
and 6). It was not surprising that capillaries were the pri-
mary site of tracer location at early times post-injection
because capillaries are the most numerous blood vessels
in the brain. ISF tracer association with capillaries and
arteries has been described previously by several groups
[22]. In contrast, tracer association with veins was incon-
sistent in different systems. Some reported no associ-
ation of ovalbumin or 3 kD dextran with veins [22];
however, another paper by this same group using 10 kD
dextran reported a significant association with veins [30].
In the present studies, we found an artery to vein (A/V)
ratio of approximately 4 to 1 for non-capillary-associated
tracer at 30 min post-injection (Table 6), and at 7 hours
post-injection this ratio was 3.1 to 1, which was not sig-
nificantly different from the 30 min time-point. Thus,
approximately, 20-30% of the tracer associated with lar-
ger vessels was associated with veins, and this tracer
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involving veins.
The explanation for the skewed A/V ratio in our tracer
clearance results remains unclear at the present time.
ISF flow is thought to be driven mainly by pressure due
to production of new ISF by brain capillary endothelial
cells [41]. Although some of the ISF appears to drain via
diffusion into the CSF [42], it is believed that much of
the perivascular ISF is collected by lymphatic vessels
surrounding blood vessels as they emerge from the skull
[22,23]. This explanation for outflow and collection of
brain ISF outflow could be applicable equally to arteries
and veins. The 4 to 1 A/V ratio seen in our experiments
may relate to the amount of BM space available around
endothelial and smooth muscle cells in vessels where the
ISF flows. The larger amount of BM associated with
smooth muscle cells in walls of arteries compared to
veins might provide an increased space for ISF flow out
of the brain on arteries versus veins.
Another explanation for the prominent detection of
ISF tracers on arteries versus veins suggests that the
contrary (or reflection) wave traveling in the reverse dir-
ection from the pulse wave created by the heart beat
might drive the ISF along the outside of arteries in the
opposite direction to the blood flow [23,43]. The ab-
sence of valves along the ISF path outside blood vessels
may be a problem for this option. However, of equal im-
portance, this proposal would not explain the clearance
of a substantial amount of ISF tracer associated with
veins.
The relative selectivity of ISF tracer for arteries versus
veins of 4 to 1 observed in our studies is in close agree-
ment with the 4.6 to 1 ratio for Aβ association with ar-
teries versus veins in leptomeninges of humans with
AD [21]. Therefore, our results support the previous
conclusion by Weller and co-workers that the vascular
specificity of ISF flow may be an important factor in
the accumulation and distribution of vascular Aβ amyl-
oid in AD [24,38]. In contrast, our present data on vas-
cular distribution of PrPres amyloid suggested that ISF
flow might be one of several factors involved in perivas-
cular PrPres distribution. Other factors, such as vas-
cular BM-derived co-factors for amyloid scaffolding,
might also be important in vascular specificity of PrP
amyloid both in the Tg44 mouse model and in
humans with familial prion disease related to expres-
sion of mutated truncated PrP.
Conclusions
Vascular distribution of PrPres amyloid in scrapie-
infected Tg44+/+ mice expressing anchorless PrP dif-
fered from the vascular distribution of ISF tracer mole-
cules followed in these same mice. Thus, although
ISF flow appeared to mediate the transport of smallmolecules such as PrP oligomers towards blood vessels,
the ISF flow alone did not completely determine the vas-
cular deposition of PrPres amyloid. We hypothesize that
other factors including basement membrane compo-
nents such as glucosaminoglycans and laminin, might
act as scaffolds to increase amyloid formation by PrP or
other proteins starting at the vascular basement mem-
brane (Figure 4). Such scaffolding molecules might differ
on different blood vessel types, and the requirements for
such factors might differ among different proteins
forming amyloid. These factors might account for the
varying vascular specificities observed in different CAA
diseases in mice and in humans.
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